Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive oil injection may keep liver cancer at bay

NCT ID NCT00116454

Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been successfully treated. The goal was to see if the treatment reduced tumor recurrence over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radioactive lipiodol (Lipiocis)
What this could lead to
If it works, this could reduce the chance of liver cancer coming back after initial treatment, potentially improving long-term survival.
What could go wrong
This is a small, completed trial with only 73 participants, so results may not apply broadly. The treatment involves radiation and may cause liver toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

73 people

The number who actually took part.

Start date

Jul 2005

Finished

Aug 2013

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women , aged between 18 and 75 years old * Cirrhosis or chronic hepatitis associated with C, B, delta infection or alcool intake or both and confirmed by liver biopsy * One or two HCC nodules treated by surgical or percutaneous ablation (ethanol, acetic acid 50% or radiofrequency). * The efficacy of the initial curative treatment will be assessed by the following criteria: alpha-fetoprotein concentration \< or equal 25ng/ml, no progression in size of the tumour demonstrated by ultrasonography and no arterial hypervascularization on CT scan imaging Exclusion Criteria: * HIV coinfection associated with a CD count\<200/mm3 and a viral charge\>5000 HIV RNA copies/ml * Documented iodine intolerance * Respiratory insufficiency * Decompensated cirrhosis (Child-Pugh score over 8) * Bilirubin concentration over 51 µmol/l * Portal or hepatic vein thrombosis * Extra-hepatic metastasis * Excessive alcohol intake (over 50g per day) * Blood platelet count below 50000/mm3 * Neutrophil count above 1500/mm3 * Creatininemia over 120µmol/l * Myocardial infarction or rhythm disorders * Psychiatric disease with hospitalization * Previous treatment for hepatocellular carcinoma * Pregnant or breastfeeding * Treatment with interferon and/or ribavirin 3 months before inclusion * Treatment with tamoxifen or somatostatin analogs or systemic chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, hepatocellular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic hepatitis hepatocellular carcinoma viral hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, hepatocellular Hepatitis, viral, human

Contacts and locations

Locations

  • Service d'Hépatologie Hôpital Saint Antoine

    Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.